Pituitary tumors are more frequent than commonly thought [1, 2]. Despite the significant progress of pituitary sciences in the last years, some pituitary adenomas still present considerable challenges in diagnosis and treatment. Most hospitals present highly trained endocrinologists, pituitary surgeons, and other supporting specialists. However, their outcome is impeded by the fragmented approach to the problems. In most centers, specialists dealing with pituitary tumors are not integrated without networking activity and explicit protocols or validation by external auditors. In that situation appeared the need for the concept of Pituitary Tumors Centers of Excellence (PTCOE). The PTCOE involves a multidisciplinary team of experts in clinical neuroendocrinology, transsphenoidal surgery, radiodiagnostic, neuropathology, and other supporting specialists. Such teamwork in a center is integrated with standard protocols and group discussions, and the outcomes are reviewed and validated by external authorities [3].

Cushing’s disease is a complex disorder characterized by chronic hypercortisolism (Cushing’s syndrome) generated by a pituitary adenoma hypersecreting adrenocorticotropic hormone (ACTH). It is probably the most challenging pituitary adenoma with considerable problems in suspecting the disease, biochemical diagnosis, and effective treatment and follow-up [4].

When signs and symptoms of the patient suggest a Cushing’s disease, the first step is to demonstrate the presence of chronic hypercortisolism and then ACTH-dependent, which needs to be performed through biochemical tests [5, 6]. Clinical endocrinologists of the PTCOE need to have a deep understanding of the capability and mechanism of each of these tests. The first step includes urinary-free cortisol in 24 h urine collection (UFC), late-night salivary cortisol (LNSC), and a low-dose dexamethasone suppression test. At the PTCOE, endocrinologists work in close liaison with laboratory specialist experts in these tests and are well aware of the efficacy, limitations, confounding factors, and interferences [7–10]. No other pituitary adenoma needs so many tests for diagnosis, with the peculiarity that sometimes they need to be repeated and that frequently all of them need to be performed to reinforce the diagnosis. One of the major problems is to differentiate Cushing’s disease from non-neoplastic hypercortisolism. As the PTCOE is a patient-centered organization [3], the patients’ clinical history and interfering disruptors need to be carefully evaluated. The following step usually involves measuring ACTH either basal or stimulated by corticotrophin-releasing hormone (CRH) or desmopressin [11, 12]. It is easy to understand that such a complex biochemical diagnosis is favored by meeting discussions by laboratory experts and endocrinologists with the high experience attained in units with a high workload.

One of the basic supports of a PTCOE is the presence of a highly experienced neuroradiologist. After the biochemical diagnosis of Cushing’s disease, another challenging point is to localize the adenoma in the pituitary. The adenoma size in Cushing’s disease is variable. However, microadenoma is frequently difficult to visualize or is not visible under magnetic resonance imaging (MRI) [3, 13]. Even adenomas are frequently so small that with the standard 1.5 T MRI near 50% of microadenomas are not visible [13–15]. Positron emission tomography to detect Cushing’s disease adenomas is unavailable in many countries, and even results are variable [16, 17]. The collaboration with experienced neuroradiologists is also relevant in the cases where inferior petrosal sinus venous sampling (IPSS) was employed to differentiate Cushing’s disease from ectopic ACTH-dependent Cushing’s syndrome [18, 19]. As the combination of laboratory and image testing is necessary for the diagnosis of Cushing’s disease as well as to exclude ectopic ACTH-secreting tumors,
this is only possible in highly specialized centers [20], being PTCOE the most logical structure for that task.

When considering the treatment, transsphenoidal surgery is currently the first-line therapy for patients with Cushing’s disease. The PTCOE [3] criteria put special emphasis on the presence of an experienced pituitary surgeon with in-depth training and who maintains expertise through a high workload [21]. The results of surgery for Cushing’s disease are highly effective in the hands of experienced surgeons [22–24]. Lower rates of positive results in the hands of less experienced surgeons are associated with a higher number of complications [22]. In any case, recurrences after pituitary surgery are possible. This caused mandatory lifelong follow-up and monitoring of the patient by the endocrine unit.

The role of the clinical endocrinology section on the PTCOE is complex, from clinical suspicion to disease control route. In the initial steps of management, and during follow-up endocrinologists are in charge of dealing directly or relying on expert consultants with the multiple complications of the disease, such as diabetes mellitus [25], hypertension, dyslipidemia, hypercoagulability, cardiovascular disease, bone comorbidities [26], and other pituitary hormones deficiency [27].

This complex task may be continued in cases not controlled after surgery or radiotherapy. In such situations, the endocrinologist must discern among the multiple medical treatments available to control hypercortisolism [28]. Currently, there are ketoconazole, cabergoline, mifepristone, metyrapone, and pasireotide, but an adequate knowledge on new drug treatments may be needed [29]. New drugs have been approved for treating CD, among which pasireotide which is a novel somatostatin receptor ligand that leads to normalization of cortisol levels in 20% of the patients. However, 50% of the patients develop serious side effects, such as hyperglycemia. Cabergoline was used with variable results, as well as alternative therapies focused on adrenal steroidogenesis, such as ketoconazole, metyrapone, osilodrostat, mitotane, etomidate, levoketoconazole, or targeting the peripheral glucocorticoid receptor as mifepristone. A clear knowledge of the different mechanisms of action, limitations, and even risk of such drugs become mandatory.

The clinical endocrinologist role starts with the suspicion and diagnosis of the disease, and follows with the overall supervision of the treatment either surgical or medical, plus control of complications. A life-long follow up be mandatory. The PTCOE in charge of the patient may incorporate expert radiotherapists either as a part of the unit or external to treat patients not controlled by surgery or medical treatment. The outcome of radiotherapy is variable and usually takes several years. In previous years, highly focused radiation was performed by stereotactic procedures such as gamma knife or proton beam before remission of the disease was attained [30].

For neurosurgeons, expertise is based on excellent previous training and a high workload [31]. The situation is less defined for clinical endocrinologists but intuitively seems similar. It is evident that when most cases see a professional, the outcome is better. For Cushing’s disease, the
problem is greater because the number of affected patients is 5 relatively small. Then, modifying the quotient between the number of specialists and the number of patients may only occur by reducing the number of specialists. That is impossible for neurosurgeons because one or a maximum of two perform such complex interventions in many hospitals. In addition, clinical endocrinologist takes care of many other pituitary diseases apart from adenomas. Therefore, it is needed to change the current scheme of experts from different divisions collaborating on a given patient to a new one denominated PTCOE that will be beneficial by definition and operate as a structured team with pre-determined meetings and fixed protocols [3]. The PTCOE is externally accredited because the periodic evaluation for outcomes performed by the accreditation commission will force to increase quality. Another option is to transform the PTCOE into a Regionalized Pituitary Tumors Center of Excellence that does not serve the inhabitants of a reduced area; instead, it serves a region with 2.5–5 million inhabitants (Fig. 1). The structure concentrates on several expert surgeons and clinical endocrinologists and attends to many patients to increase the workload. For external endocrine units to send their cases or the most difficult cases to such a regionalized structure would be better for the patient and cust-benefit the health system [3, 32].

**Funding** Open Access funding provided thanks to the CRUE-CSIC agreement with Springer Nature.

**Declarations**

**Conflict of interest** The authors declare they have no conflict of interest.

**Research involving human and animal participants** There is not involvement of persons or animals.

**Informed consent** There is not need of informed consent.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Daly AF, Tichomirowa MA, Beckers A (2009) The epidemiology and genetics of pituitary adenomas. Best Pract Res Clin Endocrinol Metab 23:543–554
2. Fernandez A, Karavitaki N, Wass JA (2010) Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol 72:377–382
3. Casanueva FF, Barkan AL, Buchfelder M et al (2017) Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE). Pituitary 20(5):489–498
4. Melmed S, Kaiser UB, Lopes MB et al (2022) Clinical biology of the pituitary adenoma. Endocr Rev. https://doi.org/10.1210/endrev/bnac010
5. Nieman LK, Biller BM, Findling JW et al (2008) The diagnosis of Cushing’s syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 93:1526–1540
6. Fleseriu M, Auchus R, Bancos I et al (2021) Consensus on diagnosis and management of Cushing’s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847–875
7. Rubinstein G, Osswald A, Hoster E et al (2020) Time to diagnosis in Cushing’s syndrome: a meta-analysis based on 5367 patients. J Clin Endocrinol Metab 105:e12-22
8. Biller BM, Grossman AB, Stewart PM et al (2008) Treatment of adrenocorticotropic-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab 93:2454–2462
9. Raff H, Carroll T (2015) Cushing’s syndrome: from physiological principles to diagnosis and clinical care. J Physiol 593:493–506
10. Galm BP, Qiao N, Klibanski A et al (2020) Accuracy of laboratory tests for the diagnosis of Cushing syndrome. J Clin Endocrinol Metab 105:2081–2094
11. Petersenn S (2021) Biochemical diagnosis of Cushing’s disease: screening and confirmatory testing. Best Pract Res Clin Endocrinol Metab 35:101519
12. Newell-Price J, Nieman LK, Reincke M et al (2020) Endocrinology in the time of COVID-19: management of Cushing’s syndrome. Eur J Endocrinol 183:G1-7
13. Buchfelder M, Nistor R, Fahrbus R et al (1993) The accuracy of CT and MR evaluation of the sella turcica for detection of adrenocorticotropic hormone-secreting adenomas in Cushing disease. AJNR Am J Neuroradiol 14:1183–1190
14. Patel V, Liu CJ, Shiroishi MS et al (2020) Ultra-high field magnetic resonance imaging for localization of corticotropin-secreting pituitary adenomas. Neuroradiology 62:1051–1054
15. MacFarlane J, Bashari WA, Senanayake R et al (2020) Advances in the imaging of pituitary tumors. Endocrinol Metab Clin North Am 49:357–373
16. Chittiboina P, Montgomery BK, Millo C et al (2015) High-resolution F-fluorodeoxyglucose positron emission tomography and magnetic resonance imaging for pituitary adenoma detection in Cushing disease. J Neurosurg 122:791–797
17. Boyle J, Patronas NJ, Smirniotopoulos J et al (2019) CRH stimulation improves F-FDG-PET detection of pituitary adenomas in Cushing’s disease. Endocrine 65:155–165
18. Oldfield EH, Chrousos GP, Schulte HM et al (1985) Preoperative lateralization of ACTH-secreting pituitary microadenomas by bilateral and simultaneous inferior petrosal venous sinus sampling. N Engl J Med 312:100–103
19. Sharma ST, Raff H, Nieman LK (2011) Prolactin as a marker of successful catheterization during IPSS in patients with ACTH-dependent Cushing’s syndrome. J Clin Endocrinol Metab 96:3687–3694
20. Nieman LK (2020) Is it time for a new approach to the differential diagnosis of ACTH-dependent Cushing syndrome? J Clin Endocrinol Metab 105:e4964–e4966
21. Swearingen B (2012) Update on pituitary surgery. J Clin Endocrinol Metab 97:1073–1081
22. Cric I, Zhao JC, Du H et al (2012) Transsphenoidal surgery for Cushing disease: experience with 136 patients. Neurosurgery 70:70–81
23. Alexandraki KI, Kaltsas GA, Isidori AM et al (2013) Long-term remission and recurrence rates in Cushing’s disease: predictive factors in a single-centre study. Eur J Endocrinol 168:639–648
24. Capatina C, Hinojosa-Amaya JM, Potana C et al (2020) Management of patients with persistent or recurrent Cushing’s disease after initial pituitary surgery. Expert Rev Endocrinol Metab 15:321–339
25. Mazziotti G, Formenti AM, Frara S et al (2017) Diabetes in Cushing disease. Curr Diab Rep 17(5):32
26. Frara S, Allora A, di Filippo L et al (2021) Osteopathy in mild adrenal Cushing’s syndrome and Cushing disease. Best Pract Res Clin Endocrinol Metab 35(2):101515
27. Formenti AM, Maffezzoni F, Doga M et al (2017) Growth hormone deficiency in treated acromegaly and active Cushing’s syndrome. Best Pract Res Clin Endocrinol Metab 31(1):79–90
28. Mancini T, Porcelli T, Giustina A (2010) Treatment of Cushing disease: overview and recent findings. Ther Clin Risk Manag 21(6):505–516
29. Fleseriu M, Castinetti F, Gadelha M et al (2022) “Consensus on diagnosis and management of Cushing’s disease: a guideline update” Osilodrostat for the treatment of Cushing’s disease: efficacy, stability, and persistence—Authors’ reply. Lancet Diabetes Endocrinol 10(6):385–387
30. Castinetti F, Nagai M, Dufour H et al (2007) Gamma knife radiosurgery is a successful adjunctive treatment in Cushing’s disease. Eur J Endocrinol 156:91–98
31. Bates PR, Carson MN, Trainer PJ et al (2008) Wide variation in surgical outcomes for acromegaly in the UK. Clin Endocrinol 68:136–142
32. Mortini P, Nocera G, Roncelli F et al (2020) The optimal numerosity of the referral population of pituitary tumors centers of excellence (PTCOE): a surgical perspective. Rev Endocr Metab Disord 21:527–536

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.